KROS
NEUTRAL
$11.21
Live
Keros Therapeutics, Inc. · NASDAQ
Target $22.57
(+101.4%)
$10.41
52W Range
$22.55
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 13, 2026
Market cap
$341.37M
P/E
4.87
ROE
19.9%
Profit margin
35.7%
Debt/Equity
0.06
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
80%
KROS presents a stark dichotomy between a perfect Piotroski F-Score (9/9) and collapsing fundamental growth. While the balance sheet is exceptionally strong with a current ratio of 15.45 and minimal debt, the company is experiencing a severe revenue contraction of -87.30% and extreme operating losses. The stock is significantly undervalued relative to its Graham Number ($28.33) and Intrinsic Value ($16.1), but this value is offset by bearish insider activity and a negative technical trend.
Key Strengths
Perfect Piotroski F-Score (9/9) indicating strong short-term financial improvement
Exceptional liquidity with a Current Ratio of 15.45
Very low leverage with a Debt/Equity ratio of 0.06
Trading at a discount to book value (P/B 0.72)
Significant upside potential relative to analyst target price of $22.57
Key Risks
Catastrophic revenue decline of -87.30% YoY
Extreme operating inefficiency with an operating margin of -7576.62%
Bearish insider sentiment with sales from CEO, CFO, and General Counsel
Strongly bearish technical trend (0/100)
High volatility and typical binary risk associated with the biotechnology sector
AI Fair Value Estimate
Based on comprehensive analysis
$15.1
+34.8% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
46
Moderate
85
20
30
95
0
AI Verdict
Speculative Value Play
Key drivers: Fortress balance sheet, Severe revenue collapse, Deep valuation discount, Insider divestment
Confidence
85%
Value
85/100
Ref P/E, PEG, Graham Number
Positives
- Price well below Graham Number ($28.33)
- P/B ratio of 0.72
- Low P/E of 4.87
Watchpoints
- Forward P/E is negative, suggesting expected losses
Future
20/100
Ref Growth rates
Positives
- High analyst target price suggests pipeline potential
Watchpoints
- Revenue growth -87.30%
- Q/Q revenue growth -87.34%
Past
30/100
Ref Historical trends
Positives
- Recent earnings surprises have been positive in some quarters
Watchpoints
- 5-year price change of -80.9%
- Consistent history of EPS misses/volatility
Health
95/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score 9/9
- Current Ratio 15.45
- Debt/Equity 0.06
Watchpoints
- Altman Z-Score not provided
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend payments
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$11.21
Analyst Target
$22.57
Upside/Downside
+101.4%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for KROS and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
KROS
Keros Therapeutics, Inc.
Primary
|
-80.9% | -70.2% | -8.5% | -28.6% | -0.6% | -6.6% |
|
CLLS
Cellectis S.A.
Peer
|
-83.4% | +71.4% | +189.7% | -12.0% | -6.7% | +6.0% |
|
LAB
Standard BioTools Inc.
Peer
|
-80.7% | -51.6% | -19.1% | -30.5% | -8.2% | -2.2% |
|
DCTH
Delcath Systems, Inc.
Peer
|
-28.7% | +68.5% | -11.4% | -10.5% | +6.0% | +4.2% |
|
AMRN
Amarin Corporation plc
Peer
|
-88.3% | -51.5% | +87.1% | +2.2% | +1.5% | +9.1% |
KRO
Keros Therapeutics, Inc.
Primary
5Y
-80.9%
3Y
-70.2%
1Y
-8.5%
6M
-28.6%
1M
-0.6%
1W
-6.6%
CLL
Cellectis S.A.
Peer
5Y
-83.4%
3Y
+71.4%
1Y
+189.7%
6M
-12.0%
1M
-6.7%
1W
+6.0%
LAB
Standard BioTools Inc.
Peer
5Y
-80.7%
3Y
-51.6%
1Y
-19.1%
6M
-30.5%
1M
-8.2%
1W
-2.2%
DCT
Delcath Systems, Inc.
Peer
5Y
-28.7%
3Y
+68.5%
1Y
-11.4%
6M
-10.5%
1M
+6.0%
1W
+4.2%
AMR
Amarin Corporation plc
Peer
5Y
-88.3%
3Y
-51.5%
1Y
+87.1%
6M
+2.2%
1M
+1.5%
1W
+9.1%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
4.87
Forward P/E
-2.22
PEG Ratio
N/A
P/B Ratio
0.72
P/S Ratio
1.4
EV/Revenue
-0.2
EV/EBITDA
-0.69
Market Cap
$341.37M
Profitability
Profit margins and return metrics
Profit Margin
35.65%
Operating Margin
-7576.62%
Gross Margin
47.91%
ROE
19.9%
ROA
9.25%
Growth
Revenue and earnings growth rates
Revenue Growth
-87.3%
Earnings Growth
N/A
Q/Q Revenue Growth
-87.34%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.06
Low debt
Current Ratio
15.45
Strong
Quick Ratio
15.1
Excellent
Cash/Share
$14.58
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Op. Margin
-7602.6%
Net Margin
-6093.8%
Total Assets
$0.3B
Liabilities
$0.0B
Equity
$0.3B
Debt/Equity
0.12x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-11
$N/A
2026-03-04
$-0.86
-90.4% surprise
2025-11-05
$-0.18
+80.5% surprise
2025-08-06
$-0.76
+32.5% surprise
Healthcare Sector Comparison
Comparing KROS against 291 companies in the Healthcare sector
(20 bullish, 99 neutral, 172 bearish)
P/E Ratio
4.87
This Stock
vs
87.11
Sector Avg
-94.4%
(Discount)
Return on Equity (ROE)
19.9%
This Stock
vs
-49.88%
Sector Avg
-139.9%
(Below Avg)
Profit Margin
35.65%
This Stock
vs
-9.43%
Sector Avg
-477.9%
(Weaker)
Debt to Equity
0.06
This Stock
vs
3.74
Sector Avg
-98.5%
(Less Debt)
Revenue Growth
-87.3%
This Stock
vs
80.78%
Sector Avg
-208.1%
(Slower)
Current Ratio
15.45
This Stock
vs
3.72
Sector Avg
+315.4%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
KROS
Keros Therapeutics, Inc.
|
NEUTRAL | $341.37M | 4.87 | 19.9% | 35.7% | $11.21 | |
|
CLLS
Cellectis S.A.
|
BEARISH | $337.99M | - | -65.3% | -84.9% | $3.36 | Compare |
|
LAB
Standard BioTools Inc.
|
BEARISH | $345.33M | - | -13.1% | -87.8% | $0.89 | Compare |
|
DCTH
Delcath Systems, Inc.
|
NEUTRAL | $336.0M | 138.14 | 3.0% | 3.2% | $9.67 | Compare |
|
AMRN
Amarin Corporation plc
|
BEARISH | $319.13M | - | -8.2% | -18.2% | $15.34 | Compare |
KROS
Keros Therapeutics, Inc.
NEUTRAL
Mkt Cap
$341M
P/E
4.9
ROE
19.9%
Price
$11.21
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-02 | SEEHRA JASBIR | Chief Executive Officer | Option Exercise | 55,000 | $16,500 |
| 2026-03-09 | BIENAIME JEAN-JACQUES | Director | Purchase | 2,000 | $22,420 |
| 2026-03-09 | NEWTON CHARLES W. | Director | Stock Award | 13,215 | - |
| 2026-02-19 | SEEHRA JASBIR | Chief Executive Officer | Sale | 7,015 | $113,433 |
| 2026-02-18 | REGNANTE KEITH C | Chief Financial Officer | Sale | 4,739 | $77,483 |
| 2026-02-18 | LERNER LORENA RAQUEL PH.D. | Officer | Sale | 3,873 | $63,324 |
| 2026-02-18 | CHO ESTHER | General Counsel | Sale | 4,745 | $77,581 |
SEEHRA JASBIR
Chief Executive Officer
2026-04-02
55,000 shares
·
$16,500
BIENAIME JEAN-JACQUES
Director
2026-03-09
2,000 shares
·
$22,420
NEWTON CHARLES W.
Director
2026-03-09
13,215 shares
SEEHRA JASBIR
Chief Executive Officer
2026-02-19
7,015 shares
·
$113,433
REGNANTE KEITH C
Chief Financial Officer
2026-02-18
4,739 shares
·
$77,483
LERNER LORENA RAQUEL PH.D.
Officer
2026-02-18
3,873 shares
·
$63,324
CHO ESTHER
General Counsel
2026-02-18
4,745 shares
·
$77,581
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
7 analysts
Wells Fargo
2026-03-05
Overweight
Overweight
B of A Securities
2025-11-28
Neutral
Neutral
Oppenheimer
2025-11-12
Outperform
Outperform
Wells Fargo
2025-11-11
Overweight
Overweight
Wedbush
2025-11-06
Neutral
Neutral
Past News Coverage
Recent headlines mentioning KROS from our newsroom.
Newest → oldest
No matching news yet.